4T1 Syngeneic Model Service for Breast Cancer

The 4T1 syngeneic model of breast cancer is a murine mammary carcinoma grown in fully immunocompetent BALB/c hosts, combining rapid local growth with aggressive, multi-organ metastasis that closely mirrors advanced human disease. Alfa Cytology delivers the complete 4T1 workflow—authenticated cell banking, subcutaneous or mammary fat-pad implantation, volume-balanced randomization, scheduled dosing and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets tailored to their program, strictly within a preclinical scope.

Overview of 4T1 Syngeneic Model for Breast Cancer

4T1 was established from a spontaneously arising mammary tumor in a BALB/c-background mouse and is distributed by ATCC as CRL-2539; over three decades it has become arguably the most heavily used syngeneic breast cancer model in existence. The line behaves like an orthodox triple-negative-like mammary adenocarcinoma: poorly differentiated, fast-growing in vitro and in vivo, and—decisively for metastasis research—spontaneously disseminates from a primary mammary or flank site to lung, liver, bone (femur and tibia), draining lymph nodes and, in some designs, brain. A quirky genetic trait underpins a classic analytical method: the cells are naturally resistant to 6-thioguanine, so excised lungs can be digested and plated under selective pressure, and every metastatic colony that grows is a colony that arose in vivo—the quantitative clonogenic metastasis assay of Aslakson and Miller that made 4T1 famous in the early 1990s.

Fig 1. Orthotopic 4T1 model (day 0 inoculation, day 8/9/11/12/14/15 treatments): caliper-tracked tumor photos day 7–15, tumor volume/weight, H&E/Ki67, and lymph node/tumor DC maturation (CD80/CD86), CD8+ T-cell and FoxP3+ Treg flow cytometry across DOX/EMV/aPD1 groups. (Sun, Mengchi, et al., 2025)

Immunologically, 4T1 is a demanding tumor. It is weakly immunogenic, recruits abundant myeloid-derived suppressor cells and regulatory T cells, and responds modestly at best to single-agent checkpoint blockade—which is precisely why the model dominates the preclinical literature on combination immunotherapy, radiation-plus-immunotherapy, nanoparticle and oncolytic approaches, and myeloid-targeting strategies. Practical performance is equally well documented: one million cells in the flank or mammary fat pad produce measurable tumors within about a week and lethal metastatic burden within four to six weeks without intervention, while luciferase-tagged 4T1-luc variants add whole-body bioluminescence tracking of primary growth and organ colonization. The trade-offs are brisk kinetics that compress dosing windows, a suppressive microenvironment that can blunt single-agent immunotherapy, and murine mammary biology that requires appropriate interpretation—all manageable with disciplined design. Within those boundaries, no syngeneic model offers a deeper publication history or a wider methodological toolkit for preclinical breast cancer research.

Cell Line Information: 4T1

Key characteristics of 4T1 and its commonly used derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, bioluminescence imaging and immune-profiling capabilities in-house, Alfa Cytology adapts every 4T1 engagement to the sponsor’s hypothesis—calibrating inoculum size, implantation site, dosing cadence and metastatic readouts so the model’s famous aggressiveness resolves into clean, decision-grade preclinical data.

Workflow of 4T1 Syngeneic Model Construction

Construction of the 4T1 syngeneic model is an implantation workflow whose quality depends on verified cells, vigorous recipients, standardized inoculation and a disciplined measurement cadence. A standard engagement runs as follows:

1. Source and qualify cells: 4T1 or 4T1-luc stocks are cleared by mycoplasma PCR and identity verification; luciferase expression is titrated in vitro with D-luciferin before expansion.
2. Prepare recipients: BALB/c mice (typically 6–8 weeks old, females for mammary-context studies) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 1 × 10⁷/mL for a 100 µL dose).
4. Implant: 1 × 10⁶ cells are injected subcutaneously into the flank, or orthotopically into the mammary fat pad where organ context is required, using consistent anatomical positioning for reproducible caliper geometry.
5. Randomize: when tumors reach palpability (around day 6–8), animals are assigned to groups balanced by tumor volume and body weight.
6. Dose and follow: test articles are administered on schedule; tumors are measured with calipers two to three times weekly (volume typically π/6 × length × width × height), with bioluminescence substituted or added for 4T1-luc cohorts; body weight and clinical status are logged in parallel.
7. Terminate and analyze: tumors are resected and weighed; lungs, liver, lymph nodes and bones are inspected for metastasis, with digested lungs plated under 6-thioguanine selection for clonogenic colony counting; tissues then enter histopathology, immunohistochemistry, flow-cytometric immune profiling and molecular analysis.

Fig 2. 4T1 Syngeneic Model construction workflow.

Case Study-4T1 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the 4T1 platform: establishment-phase optimization of inoculum and implant site, in vivo growth tracking by caliper or bioluminescence, combination immunotherapy and myeloid-targeting trials, and multi-organ metastasis quantification by ex vivo imaging, histology and 6-thioguanine clonogenic counting. Representative growth curves, imaging series and endpoint summaries can be shared upon request and will be updated as new programs wrap up.

Why Choose Alfa Cytology?

For a model this aggressive and this heavily published, execution quality is what separates signal from noise—and it is where Alfa Cytology concentrates its effort:

• Uniform, high-take implantation by a team working to fixed anatomical positions, with a fat-pad orthotopic option on request.
• Authenticated 4T1 and 4T1-luc banks, with GFP variants available for specialized readouts.
• Capability with the 6-thioguanine clonogenic assay—the quantitative gold standard for lung metastasis.
• An immunocompetent BALB/c host with a deeply characterized suppressive microenvironment for combination-therapy design.
• An endpoint menu running from efficacy and multi-organ metastasis counts to histopathology, IHC and flow cytometry.
• Dosing calendars engineered around 4T1’s brisk kinetics so compressed windows still deliver interpretable data.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Considering the 4T1 syngeneic breast cancer model for your next preclinical study? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.